Myocardial metabolic background on chemotherapy and means of their correction

• DOI: 10.26442/cs45027
• Publication Date: 2021-02-18T11:49:46Z
• Authors: Yu. A Vasyuk; E. L Shkolnik; V. V Nesvetov; L. D Shkolnik; G. V Varlan; A. V Pilschikov
• Keywords: Cardiotoxicity

Recent years have seen significant progress in the treatment of many oncologicaldiseases associated with development new chemotherapeutic agents. Typically, they are used combination classical chemotherapy regimens that in-clude doxorubicin. In background this combined prolongation life patients was noted, but at same time risk cardiotoxicity considerably increased. The survey provides information about cardiomyocytesmetabolic disorders during therapy anthracyclines, discussing possibility pathogenetic and prevention.